Regeneron's COVID-19 antibody cocktail arrives in Czech Republic

The first delivery of covid-19 from Regeneron arrived in the Czech Republic this morning. Delivery to hospitals interested in the drug will begin next week. There are 4,000 doses in the first delivery. The exact amount will arrive in April and May. The drug is intended for patients who are at risk of a severe course of the disease. It should be given to them shortly after a positive covid-19 test.

Pešina stated that the delivery arrived at the warehouse in Prague before ten o’clock. “We have already received requests for the allocation and delivery of the first doses from the coordinating pharmacy of the University Hospital in Motol. We expect a list from the University Hospital Brno. Distribution should start at the beginning of next week,” the spokesman said.

The fact that the medicine arrived in the Czech Republic was confirmed in the Chamber of Deputies today by Prime Minister Andrej Babiš when he justified the government’s request to extend the emergency state. “If we have a medicine here that works, then we need citizens to know about it, to demand it,” Babiš said.

The Ministry of Health authorized using this unregistered drug in early March, granting an exemption for 12,000 doses of the preparation.

Healthcare professionals may administer the medicine to patients over 12 years of age who weigh at least 40 kilograms and are at high risk of deteriorating their health. These may include but are not limited to transplant patients, cancer, hemato-cancer or autoimmune neurological diseases, type 1 diabetes, or people with high obesity. The drug is intended for patients who do not yet require hospitalization for covid-19. The disease symptoms do not last longer than seven days and have not elapsed more than three days after a positive coronavirus test.

The medicine is a combination of the antibodies casirivimab and imdevimab, which are proteins that are supposed to prevent the virus from entering human cells. Currently used in the US, the European Medicines Agency (EMA) launched its ongoing evaluation in early February. Germany was the first in the European Union to decide to use this drug experimentally. The then US President Donald Trump also underwent treatment with this drug in the autumn.

In February, the ministry authorized using a similar drug of this type, bamlanivimab, from Eli Lilly. There are 3,000 doses in the Czech Republic. It is being delivered from the Thomayer University Hospital in Prague. According to today’s Law, only 773 packages of the drug have been given so far. According to the daily, the hospital claims that it is difficult to find a high-risk patient who meets administration conditions. According to some doctors, the criteria for using bamlanivimab are too strict.

The first delivery of covid-19 from Regeneron arrived in the Czech Republic this morning. Delivery to hospitals interested in the drug will begin next week. There are 4,000 doses in the first delivery. The exact amount will arrive in April and May. The drug is intended for patients who are at risk of a severe course of the disease. It should be given to them shortly after a positive covid-19 test.

Pešina stated that the delivery arrived at the warehouse in Prague before ten o’clock. “We have already received requests for the allocation and delivery of the first doses from the coordinating pharmacy of the University Hospital in Motol. We expect a list from the University Hospital Brno. Distribution should start at the beginning of next week,” the spokesman said.

The fact that the medicine arrived in the Czech Republic was confirmed in the Chamber of Deputies today by Prime Minister Andrej Babiš when he justified the government’s request to extend the emergency state. “If we have a medicine here that works, then we need citizens to know about it, to demand it,” Babiš said.

The Ministry of Health authorized using this unregistered drug in early March, granting an exemption for 12,000 doses of the preparation.

Healthcare professionals may administer the medicine to patients over 12 years of age who weigh at least 40 kilograms and are at high risk of deteriorating their health. These may include but are not limited to transplant patients, cancer, hemato-cancer or autoimmune neurological diseases, type 1 diabetes, or people with high obesity. The drug is intended for patients who do not yet require hospitalization for covid-19. The disease symptoms do not last longer than seven days and have not elapsed more than three days after a positive coronavirus test.

The medicine is a combination of the antibodies casirivimab and imdevimab, which are proteins that are supposed to prevent the virus from entering human cells. Currently used in the US, the European Medicines Agency (EMA) launched its ongoing evaluation in early February. Germany was the first in the European Union to decide to use this drug experimentally. The then US President Donald Trump also underwent treatment with this drug in the autumn.

In February, the ministry authorized using a similar drug of this type, bamlanivimab, from Eli Lilly. There are 3,000 doses in the Czech Republic. It is being delivered from the Thomayer University Hospital in Prague. According to today’s Law, only 773 packages of the drug have been given so far. According to the daily, the hospital claims that it is difficult to find a high-risk patient who meets administration conditions. According to some doctors, the criteria for using bamlanivimab are too strict.